Reference values for N-terminal Pro-brain natriuretic peptide in premature infants during their first weeks of life

Agnes-Sophie Fritz1 • Titus Keller1 • Angela Kribs1 • Christoph Hünseler1

Received: 21 August 2020 / Revised: 17 October 2020 / Accepted: 23 October 2020
© The Author(s) 2020

Abstract
The aim of our study was to observe the temporal distribution of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) in premature infants of ≤31 weeks of gestational age (GA) during the first weeks of life. NT-proBNP values of 118 preterm infants born ≤31 weeks GA were determined during the first week of life, after 4 ± 1 weeks of life, and at a corrected GA of 36 ± 2 weeks. Infants were divided into two groups: those without relevant complications and those with complications related to prematurity. NT-proBNP values of infants without complications define our exploratory reference values. The Median NT-proBNP level of these infants was 1896 ng/l (n = 27, interquartile range (IQR): 1277–5200) during the first week of life, 463 ng/l (n = 26, IQR: 364–704) at 4 ± 1 weeks of life, and 824 ng/l (n = 33, IQR: 714–1233) at a corrected GA of 36 ± 2 weeks. Infants born < 28 + 0 weeks GA had significantly higher NT-proBNP values (n = 9, median: 5200, IQR: 1750–8972) than infants born ≥ 28 + 0–31 weeks GA (n = 18, median: 1528, IQR: 838–3052; p = 0.017). Growth restriction or PDA status could not account for the difference in NT-proBNP values between GA groups.

Conclusions: The results of our observational and cross-sectional study describe exploratory reference values for NT-proBNP levels in preterm infants of ≤31 weeks GA according to postnatal age. NT-proBNP levels during the first week of life are high and widely distributed in preterm infants and decrease subsequently to reach a distinctly lower and stable plateau at around 1 month of life. Our results suggest an influence of GA on NT-proBNP values in the first week of life.

What is Known:
• Several complications related to prematurity, e.g., hemodynamically significant PDA, pulmonary hypertension, bronchopulmonary dysplasia, and retinopathy of prematurity, have been associated with a temporary rise in NT-proBNP values in preterm infants during their first weeks of life.
What is New:
• This observational study provides reference values for NT-proBNP levels of very and extremely preterm infants during their first weeks of life.
• In premature infants without complications, NT-proBNP values during their first week of life depend on gestational age at birth.

Keywords N-terminal pro-brain natriuretic peptide • Preterm infant • Reference values

Communicated by Daniele De Luca

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00431-020-03853-8.

* Agnes-Sophie Fritz agnessophiefritz@web.de

† Titus Keller titus.keller@uk-koeln.de

Angela Kribs angela.kribs@uk-koeln.de

Christoph Hünseler christoph.huenseler@uk-koeln.de

1 Neonatal Intensive Care Unit, University Hospital in Cologne, Kerpener Str. 34, 50937 Cologne, Germany

Abbreviations

- BNP: Brain natriuretic peptide
- BPD: Bronchopulmonary dysplasia
- CRP: C-reactive protein
- GA: Gestational age
- hsPDA: Hemodynamically significant patent ductus arteriosus
- IQR: Interquartile range
- IVH: Intraventricular hemorrhage
- La:Ao: Left atrial to aortic root ratio
- NICU: Neonatal Intensive Care Unit
- NT-proBNP: N-terminal pro-brain natriuretic peptide
- PH: Pulmonary hypertension
- ROP: Retinopathy of prematurity
Introduction

Brain natriuretic peptide (BNP) consists of 32 amino acids, is predominantly produced in cardiomyocytes of the ventricles of the heart, and is secreted in response to cardiac stress, e.g., to volume expansion or pressure overload to regulate blood pressure by increasing diuresis, natriuresis, and vasodilation. Cardiomyocytes secrete an inactive precursor proBNP which is then cleaved into the active BNP and the inactive N-terminal pro BNP (NT-proBNP) [1]. NT-proBNP shows more stability in vitro and has a longer half-life than BNP (120 min vs. 22 min) [2]. NT-proBNP and BNP are renally excreted and particularly NT-proBNP plasma level is known to increase with decreased kidney function [3, 4]. BNP is an established marker of congestive heart failure in adults [5].

NT-proBNP is associated with different diseases of prematurity; increased NT-proBNP and BNP levels have been found in infants with hemodynamically significant patent ductus arteriosus (hsPDA) [6–9], bronchopulmonary dysplasia (BPD) [10–15], pulmonary hypertension (PH) [16–22], retinopathy of prematurity (ROP) [23, 24], inflammation or sepsis [25–27], and congenital heart diseases [28, 29], but published data remain inconclusive.

Currently, there are no established and validated normal range of values for very and extremely preterm infants and the results seem to vary depending on gestational age (GA), the postnatal age of testing, the diagnostic test kits used, and the underlying conditions of the patients. The aim of this observational study is to describe exploratory reference values of serum NT-proBNP in premature infants of ≤31 weeks of GA during their first weeks of life.

Materials and methods

In this retrospective observational analysis data, 118 preterm infants ≤31 weeks GA treated between October 1, 2017, and June 30, 2019, in the Neonatal Intensive Care Unit (NICU) of the Children’s Hospital of the University Hospital in Cologne, Germany, were included. The study was approved by the Bioethics Committee of the University of Cologne, and parental consent was not required due to the routine collection of NT-proBNP. Determination of NT-proBNP levels in any preterm infant born <32 weeks GA is part of routine blood collections at our institution, mainly to detect infants at risk for the development of PH and BPD. NT-proBNP measurements are routinely done in the first week of life, around day 28 of life, and when infants reach a corrected GA of 36 weeks.

The last two sampling times were chosen according to the critical periods defining BPD.

Due to practical and clinical conditions timing of NT-proBNP, measurements partly differ from the institutional protocol and the following three sampling times were identified: day 2 to 11 of life (in the following called: first week of life), day 18 to 36 of life (4 ± 1 weeks of life), and when the preterm infants reached a corrected GA of 34 ± 3 to 40 ± 3 weeks (corrected GA of 36 ± 2 weeks). If a preterm infant had multiple samples drawn during the same sampling time, the higher NT-proBNP value was chosen. Missing values emerged randomly or were due to a condition of the neonate that did not allow blood sampling, a potential source of bias.

Figure 1 shows the different sampling times according to weeks of life. The samplings at 4 ± 1 weeks of life and at a corrected GA of 36 ± 2 weeks partly overlap due to the possibility that in less premature infants, the chronological age of around 4 weeks overlaps with the corrected GA of 36 weeks. Samplings were included if they could be assigned to one sampling time.

We stratified the cohort into infants without relevant complications and those with complications related to prematurity. If one infant had any of the following complications at any time, all its NT-proBNP values were analyzed in the group with complications. The following criteria define the different complications:

I. Infection: elevated laboratory values (interleukin-6 > 50 ng/l, C-reactive protein (CRP) > 5 mg/l, leucocytes > 20,000/μl or left shift) or clinical signs of infection with subsequent antibiotic treatment

II. Hemodynamically significant PDA: two of the following criteria were observed by echocardiography: (1) diameter of the ductus arteriosus: ≥2.0 mm, (2) degree of pulmonary overflow: left atrial to aortic root ratio (La:Ao) ≥1.4, (3) retrograde descending aortic flow, (4) organ blood flow: low antegrade flow in systole or diastole or absent/reversed diastolic flow

III. BPD: definition according to Jobe [30]

IV. Pulmonary hypertension: defined by (1) elevated tricuspid regurgitation jet velocity with an estimation of RV pressure of more than 25 mmHg (depending on systemic pressure: > 50% of systemic pressure), (2) interventricular septum-configuration: flat or bowed to the left, (3) right to left or bidirectional shunting at the patent foramen ovale or PDA [31]

V. ROP stage 2 with plus disease or higher according to the international definition of ROP [32]

VI. Intraventricular hemorrhage (IVH) grade 2 or higher according to Papile [33]

VII. Pulmonary complications, e.g., pneumothorax or pulmonary interstitial emphysema

VIII. Intestinal complications, e.g., all stages of necrotizing enterocolitis (NEC) according to the modified Bell
staging criteria [34], focal intestinal perforation (FIP), or gastric perforation.

Infants with major congenital heart diseases, chromosomal abnormalities, or kidney diseases were excluded. Additionally, we tested the influence of each complication on NT-proBNP values separately comparing the NT-proBNP values of infants with and without the respective complication.

In a second step, we investigated if our exploratory NT-proBNP reference values depend on GA at birth and divided the infants according to the World Health Organization’s (WHO) definition of extremely (born < 28 weeks GA) and very preterm infants (born between 28 and 32 weeks GA).

Originally based on a longitudinal study design, the composition of groups differs over time resulting that the study holds the characteristics of a cross-sectional study.

Arterial, central venous, peripheral venous, or capillary blood samples were analyzed on the Cobas E801 analyzer using the Elecsys proBNP II method (Roche Diagnostics). Different types of blood sampling presumably lead to comparable NT-proBNP values [35, 36]. The measuring range for the used method is 5–35,000 ng/l. Values above the upper measuring limit are reported as 35,000 ng/l or up to 70,000 ng/l for 2-fold diluted samples. The cut-off value for the diagnosis of heart failure in adults is 125 ng/l for the used test kit. According to Roche Diagnostics considering concentration-dependent scattering, the intra-assay coefficient of variation for human serum varied between 1.5 and 9.2%, and the inter-assay coefficient of variation for human serum between 2.6 and 12.5% [37]. High levels of hemoglobin, triglycerides, or bilirubin do not seem to interfere with NT-proBNP analysis [38]. Different NT-proBNP assays show poor concordance. Therefore, assay-specific reference and cut-off values must be considered when interpreting NT-proBNP levels and patients should be monitored using the same assay [39, 40].

**Statistical analysis**

Statistical analysis was performed using the Statistical Package for Social Sciences, v24 (IBM SPSS, Chicago, Ill., USA). The Mann-Whitney U test was used to compare NT-proBNP concentrations between groups, and the Friedman test to evaluate changes in NT-proBNP levels over time. A two-sided p value of < 0.05 was considered statistically significant.

**Results**

**Patient cohort**

Characteristics and postnatal course of the 118 patients, including the prevalence of prematurity-related complications in our cohort, are described in Table 1. The median GA at birth was 26 ± 5 weeks and the median birth weight is 900
A. Exploratory reference values for NT-proBNP in preterm infants ≤ 31 weeks GA during the first weeks of life

NT-proBNP values of infants without relevant complications related to prematurity define our exploratory reference values. Comparing NT-proBNP values of infants without major complications to those of infants with complications using the Mann-Whitney U test, NT-proBNP values of preterm infants with relevant complications were significantly higher during the first week of life (n = 27, median: 1896, IQR: 1277–5200 vs. n = 34, median: 4058, IQR: 2189–10,751; p = 0.004) and at 4 ± 1 weeks of life (n = 26, median: 463, IQR: 364–704 vs. n = 45, median: 920, IQR: 601–1630; p < 0.001). At a corrected GA of 36 ± 2 weeks, preterm infants without relevant complications had significantly higher NT-proBNP values compared to the group with complications (n = 33, median: 824, IQR: 714–1232 vs. n = 34, median: 671, IQR: 449–989; p = 0.032). The nomogram in Fig. 2 describes the 5th, 10th, 25th, 50th, 75th, 90th, and 95th percentile for NT-proBNP values of preterm infants without and with complications over the first weeks of life. Tables 2 and 3 (see Online Supplement) show the corresponding values. We separately analyzed the NT-proBNP values of the infants displaying the single complications (infection, hsPDA, BPD, PH, ROP, IVH, pulmonary and intestinal complications) and compared them to the NT-proBNP values of infants without the respective complication. We could demonstrate significantly higher NT-proBNP values in infants with hsPDA (first week of life, p = 0.034), BPD (first week of life, p = 0.021; 4 ± 1 weeks of life, p < 0.001), PH (4 ± 1 weeks of life, p < 0.001), ROP stage 2 with plus disease or higher (4 ± 1 weeks of life, p = 0.007), infection (first week of life, p = 0.02, 4 ± 1 weeks of life, p = 0.032), IVH grade 2 or higher (first week of life, p = 0.014; 4 ± 1 weeks of life, p = 0.001), and intestinal complications like NEC, FIP, or gastric perforation (first week of life, p = 0.029; 4 ± 1 weeks of life, p = 0.007). The exact values are given in Tables 5–28 in the Online Supplement.

B. Dependency of exploratory NT-proBNP reference values on the gestational age at birth

Infants without relevant complications that define our exploratory reference values were divided into two groups depending on GA at birth: extremely preterm infants (< 28 + 0 weeks GA) and very preterm infants (≥ 28 + 0–31 weeks GA). During the first week of life, NT-proBNP values of the extremely preterm infants (n = 9, median: 5200, IQR: 1750–8972) were significantly higher compared to the values of the very preterm infants (n = 18, median: 1528, IQR: 838–3052; p = 0.017). At 4 ± 1 weeks of life and at a corrected GA of 36 ± 2 weeks, no statistically significant differences in NT-proBNP values were seen between the different GA groups (p = 0.421, p = 0.703).

---

**Table 1** Characteristics and postnatal course of patients

| Characteristics                         | All infants: n = 118 number (percentage) or median (IQR) |
|-----------------------------------------|---------------------------------------------------------|
| Gender, male                            | 69 (59%)                                                |
| Gestational age at birth (weeks)        | 26 + 5 (24 + 5–29 + 2)                                  |
| Birth weight (g)                        | 900 (630–1220)                                          |
| SGA (birth weight < 3rd percentile)    | 9 (8%)                                                  |
| 5′ Apgar score                         | 7 (7–8)                                                 |
| CRIB-II score                          | 5 (2–9)                                                 |
| C-section                               | 108 (92%)                                               |
| Prenatal steroids                       | 90 (76%)                                                |
| Complete                                | 67 (57%)                                                |
| Incomplete                              | 23 (19%)                                                |
| Postnatal course                        |                                                         |
| Chorioamnionitis                        | 12 (10%)                                                |
| Infection                               | 35 (30%)                                                |
| PDA                                     | 94 (80%)                                                 |
| Non-hemodynamically significant         | 76 (64%)                                                |
| Hemodynamically significant             | 18 (15%)                                                |
| Pulmonary hypertension [33]             | 24 (20%)                                                |
| BPD [32]                                | 37 (31%)                                                |
| Mild                                    | 26 (22%)                                                |
| Moderate                                | 6 (5%)                                                  |
| Severe                                  | 5 (4%)                                                  |
| ROP [34]                                | 101 (86%)                                               |
| Stage 1                                 | 79 (67%)                                                |
| Stage 2                                 | 12 (10%)                                                |
| Stage 3                                 | 10 (8%)                                                 |
| IVH [35]                                | 37 (31%)                                                |
| Grade 1                                 | 23 (19%)                                                |
| Grade 2                                 | 3 (3%)                                                  |
| Grade 3                                 | 11 (9%)                                                 |
| Intestinal complications                | 15 (13%)                                                |
| NEC [36]                                | 4 (3%)                                                  |
| FIP                                     | 9 (8%)                                                  |
| Gastric perforation                     | 2 (2%)                                                  |
| Pulmonary complications                  | 10 (8%)                                                 |
| (pneumothorax, pulmonary interstitial emphysema) |             |
| Duration of ventilation                 | 835 (231–1564)                                          |
| (mechanical ventilation and CPAP)       | (hours)                                                 |
| Duration of oxygen supply > 21% (days)  | 3 (1–46)                                                |

Nine preterm neonates were small for gestational age (SGA; defined by a birth weight < 3rd percentile). The median 5′ Apgar score was 7 and the median CRIB-II score 5. A total of 108 patients were delivered by C-section and mothers of 90 infants had prenatal steroids administered. One patient died after 5 days because of severe IVH.
During the first week of life, no infant of the two different GA groups was SGA. Eight (89%) infants of the extremely preterm infants had a nhsPDA, in comparison to 8 (44%) of the very preterm infants. NT-proBNP values of infants with different PDA status (no vs. nhsPDA) did not differ significantly within the groups of extremely and very preterm infants ($p=0.222$, $p=0.0101$). In multiple linear regression analysis ($p=0.051$, $R^2=0.219$), GA at birth but not PDA status proved to have a significant correlation with NT-proBNP values during the first week of life ($p=0.038$).

C. Development of NT-proBNP values over time

NT-proBNP values showed a very wide range of distribution (minimum: 148 ng/l, maximum: 39,340 ng/l) with the highest values during the first week of life. Values then decreased to a distinctly lower and stable plateau at 4 ± 1 weeks of life and at a corrected GA of 36 ± 2 weeks (Fig. 3, Table 4 in Online Supplement).

Comparing the NT-proBNP values within the infants without and with complications using the Friedman test, NT-proBNP values were significantly higher during the first week of life than at 4 ± 1 weeks of life and at a corrected GA of at 36 ± 2 weeks. Between NT-proBNP values of 4 ± 1 weeks of life and a corrected GA of at 36 ± 2 weeks, no statistical difference was seen (Fig. 2).

Discussion

The current study investigated the temporal distribution of NT-proBNP values and describes exploratory reference values in premature infants born ≤ 31 weeks GA.
Most studies investigating NT-proBNP values in preterm infants have focused on the presence of a defined complication of prematurity and compared the NT-proBNP values to values of infants not displaying this complication—irrespective of other possible confounding complications. We aimed to exclude all conditions that could possibly influence NT-proBNP values. For some of these conditions, there is strong, study-based evidence and a direct pathophysiological link on how they influence NT-proBNP levels in preterm neonates, among them hsPDA [6–9], BPD [10–15], and PH [16–22]. For others, e.g., ROP and infection, the pathophysiological link to NT-proBNP is not as clear. Still, high urinary NT-proBNP levels and subsequent ROP development have been described, in a multicenter trial with 1000 patients [23]. A correlation between NT-proBNP and inflammation or sepsis observed in some studies is explained in part by acute ventricular dysfunction in septic patients [26] and in part by markers of inflammation that may selectively influence BNP gene expression [25, 27]. For some conditions, including intestinal complications (NEC, FIP, gastric perforation), pulmonary complications (pneumothorax, PIE), and IVH, data regarding the relationship between NT-proBNP plasma levels and the complications are still lacking. Nevertheless, these conditions are often accompanied by hemodynamic changes due to elevated intra-abdominal or intra-thoracic pressures, volume depletion, and inflammation that are likely to affect NT-proBNP levels.

Indeed, in an internal analysis, we were able to show significant higher NT-proBNP values for most of our complications. However, further analysis, including multivariate regression analysis, can potentially shed more light on these relationships.

NT-proBNP values of infants with complications were significantly higher during the first week of life and at 4 ± 1 weeks of life compared to those without complications. NT-proBNP values at a corrected GA of 36 ± 2 weeks stand out as infants without complications tended to have higher values compared to those with complications. With increasing postnatal age, NT-proBNP values decline after birth. Infants with complications and a more likely lower GA at birth had a higher chronological age at 36 weeks corrected GA compared to the reference group which may represent in lower NT-
proBNP levels. In contrast, in infants without major complications, NT-proBNP values increased from 4 ± 1 weeks of life to the corrected GA of 36 ± 2 weeks. Interestingly, Harris et al. studied NT-proBNP levels in a comparable cohort of preterm infants and described a similar increase in values of the control group at a corrected GA of 36 weeks [6]. On the other hand, Nir described a continuous decline in values with increasing chronological age in healthy term neonates [41]. It is important to emphasize that the median GA of our cohort is 26 ± 5 weeks and the median birth weight is 900 g. Hence, our cohort is shifted to extremely premature infants complicating the comparison to other epidemiological studies in premature infants.

NT-proBNP levels of our study as in others [6, 41] peak in the first days after birth. Values then decrease to lower levels with narrow ranges, which are though much higher than the normal range known from healthy adults. The peak in the first days of life is most likely due to the significant circulatory changes during transition from fetal to neonatal circulation. During this period, the individual trends in one patient’s values may be more useful than generally defined reference values.

Exploratory reference values in infants < 28 weeks GA were significantly higher than in those of 28–31 weeks GA at birth. We further investigated if comorbidities could account for the observed difference, as several studies have previously assumed [6, 42, 43]. Neither growth restriction nor different PDA status (no vs. nhsPDA) could account for the observed difference. Further studies are required to investigate the dependency of NT-proBNP values on the GA at birth which is complicated by the fact that only a small number of extremely preterm infants remain without relevant comorbidities in the early postnatal life.

Future studies that aim to help define NT-proBNP reference values should be designed as prospective studies, define more strictly sampling times, and evaluate NT-proBNP values longitudinally with an increased number of patients to gain more statistical power.

**Study limitations**

As the composition of patients within a group differs over time, the study carries characteristics of a cross-sectional study. Blood collection differed from the time points defined in the NICU standard which may have had an impact especially on the results during the first week of life when significant changes may occur daily. Another study limitation is the retrospective nature and the resulting limitation of standardization. The moderate sample size does not allow the definition of generally accepted reference values but describes exploratory ranges.

**Conclusions**

The results of our observational and cross-sectional study describe exploratory reference values for NT-proBNP in preterm infants ≤ 31 weeks GA in the early postnatal life. NT-proBNP levels during the first week of life are high and widely distributed in preterm infants and decrease subsequently to reach a distinctly lower and stable plateau at around 1 month of life. Our results suggest an influence of GA on NT-proBNP values in the first week of life.

**Authors’ contributions** A.F. collected patient data, performed the statistical analysis, and wrote the manuscript. T.K. contributed to the interpretation of the results. A.K. and C.H. helped supervise the project. C.H. conceived the original idea. All authors discussed the results and contributed to the final manuscript.

**Funding** Open Access funding enabled and organized by Projekt DEAL.

**Data availability** Derived data supporting the findings of this study are available from the corresponding author upon request.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Ethical approval** The study was approved by the Bioethics Committee of the University of Cologne and performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.

**Consent to participate** Parental consent was not required due to the routine collection of NT-proBNP.

**Consent for publication** In this retrospective and monocentric study, patients remain unidentifiable and in consultation with the Bioethics Committee of the University of Cologne, no consent for publication was required.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Levin ER, Gardner DG, Samson WK (1998) Natriuretic peptides. N Engl J Med 339:321–328. https://doi.org/10.1056/NEJM199807303390507
Vanderheyden M, Bartunek J, Goethals M (2004) Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 6:261–268. https://doi.org/10.1016/j.ejheart.2004.01.004

Tagore R, Ling LH, Yang H, Daw HY, Chan YH, Sethi SK (2008) Natriuretic peptides in chronic kidney disease. Clin J Am Soc Nephrol 3:1644–1651. https://doi.org/10.2215/CJN.00850208

Takase H, Dohi Y (2014) Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship. Eur J Clin Invest 44(3):303–308. https://doi.org/10.1111/eci.12234

Gotze JP, Kastrup J (2001) Plasma pro-brain natriuretic peptides are a strong biochemical markers in clinical cardiology. Scand J Clin Lab Invest (Suppl) 234:47–51. https://doi.org/10.1080/cl.61.234.47.51

Harris SL, More K, Dixon B, Troughton R, Pemberton C, Horwood J, Ellis N, Austin N (2018) Factors affecting N-terminal pro-B-type natriuretic peptide levels in preterm infants and use in determination of haemodynamic significance of patent ductus arteriosus. Eur J Pediatr 177:521–532. https://doi.org/10.1007/s00431-018-3089-y

Letshwiti JB, Sire J, O’Kelly R, Miletin J (2014) Serial N-terminal pro-brain natriuretic peptide measurement as a predictor of significant patent ductus arteriosus in preterm infants beyond the first week of life. Eur J Pediatr 173:1491–1496. https://doi.org/10.1007/s00431-014-2350-2

Mine K, Ohashi A, Tsuji S, Nakashima JI, Hirabayashi M, Kaneko K (2013) B-type natriuretic peptide for assessment of haemodynamically significant patent ductus arteriosus in premature infants. Acta Paediatr 102:347–352. https://doi.org/10.1111/apa.12273

Kalra VK, DeBari VA, Zauk A, Kataria P, Myridakis D, Kiblawi F (2011) Point-of-care testing for B-type natriuretic peptide in premature neonates with patent ductus arteriosus. Ann Clin Lab Sci 41:131–137

Méndez-Abad P, Zafra-Rodríguez P, Lubíñán-López S, Benavente-Fernández I (2019) NTproBNP is a useful early biomarker of bronchopulmonary dysplasia in very low birth weight infants. Eur J Pediatr 178:755–761. https://doi.org/10.1007/s00431-019-03347-2

Zhou L, Xiang X, Wang L, Chen X, Zhu J, Xia H (2019) N-terminal pro-B-type natriuretic peptide as a biomarker of bronchopulmonary dysplasia or death in preterm infants: a retrospective cohort analysis. Front Pediatr 7:1–7. https://doi.org/10.3389/fped.2019.00166

Joseph L, Nir A, Hammerman C, Goldberg S, Ben Shalom E, Picard E (2010) N-terminal pro-B-type natriuretic peptide as a marker of bronchopulmonary dysplasia in premature infants. Am J Perinatol 27:381–386. https://doi.org/10.1056/s-0029-1243312

Kalra VK, Aggarwal S, Arora P, Natarajan G (2014) B-type natriuretic peptide levels in preterm neonates with bronchopulmonary dysplasia: a marker of severity? Pediatr Pulmonol 49:1106–1111. https://doi.org/10.1002/ppul.22942

Montaner A, Pinillos R, Galve Z, Boix H, de la cuesta C, Jimenez L, Samper P, Rite S (2017) Brain natriuretic propeptide as an early marker of bronchopulmonary dysplasia or death in the preterm newborn. Klin Padiatr 229:223–228. https://doi.org/10.1055/s-0043-115979

Sellner A, Hjortdal VE, Bjerve JV, Schmidt MR, McNamara PJ, Bech BH, Henriksen TB (2015) N-terminal pro-B-type natriuretic peptide as a marker of bronchopulmonary dysplasia or death in very preterm neonates: a cohort study. PLoS One 10:1–11. https://doi.org/10.1371/journal.pone.0140079

ten Kate CA, Tibboel D, Kraemer US (2015) B-type natriuretic peptide as a parameter for pulmonary hypertension in children. A systematic review. Eur J Pediatr 174:1267–1275. https://doi.org/10.1007/s00431-015-2619-0

Shah N, Natarajan G, Aggarwal S (2015) B-Type Natriuretic Peptide: Biomarker of Persistent Pulmonary Hypertension of the Newborn? Am J Perinatol 32:1045–1049. https://doi.org/10.1055/s-0035-1548540

König K, Guy KJ, Walsh G, Drew SM, Barfield CP (2016) Association of BNP, NTproBNP, and early postnatal pulmonary hypertension in very preterm infants. Pediatr Pulmonol 51:820–824. https://doi.org/10.1002/ppul.23391

Vijberveld DC, Benders MJNL, Kemperman H et al (2012) B-Type Natriuretic Peptide and Rebound during Treatment for Persistent Pulmonary Hypertension. J Pediatr 160:111–115.e11. https://doi.org/10.1016/j.jpeds.2011.06.038

König K, Guy KJ, Nold-Petry CA, Barfield CP, Walsh G, Drew SM, Veldman A, Nold MF, Casalaz DM (2016) BNP, troponin I, and YKL-40 as screening markers in extremely preterm infants at risk for pulmonary hypertension associated with bronchopulmonary dysplasia. Am J Phys Lung Cell Mol Phys 311:L1076–L1081. https://doi.org/10.1152/ajplung.00344.2016

Montgomery AM, Bazzy-Asaad A, Asnic JD, Bizzarro MJ, Ehrenkranz RA, Weismann CG (2016) Biochemical screening for pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Neonatology 109:190–194. https://doi.org/10.1159/000442043

Sims B, Cuna A, Kandasamy J, Fineberg N (2013) B-type natriuretic peptide is a biomarker for pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Res Rep Neonatol 3:33–36. https://doi.org/10.2147/rmn.s42236

Bührer C, Erdeve Ö, van Kaam A (2017) N-terminal B-type natriuretic peptide urinary concentrations and retinopathy of prematurity. Pediatr Res 82:958–963. https://doi.org/10.1007/prp.2017.179

Czernek C, Metze B, Müller C, Bührer C (2019) Urinary N-terminal B-type natriuretic peptide predicts severe retinopathy of prematurity. Pediatrics 128:545–549. https://doi.org/10.1542/peds.2011-0603

Otsubo Y, Hashimoto K, Kanbe T, Sumi M, Moriiuchi H (2017) Association of cord blood chemokines & other biomarkers with neonatal complications following intrauterine inflammation. PLoS One 12:1–12. https://doi.org/10.1371/journal.pone.0175082

Fried I, Bar-Oz B, Algar N, Fried E, Avivi S, Jeffer I, Perles Z, Rein AJJT, Zonis Z, Bass R, Nir A (2006) Comparison of N-terminal pro-B-type natriuretic peptide levels in critically ill children with sepsis versus acute left ventricular dysfunction. Pediatrics 118:1165–1168. https://doi.org/10.1542/peds.2006-0569

Ogawa T, de Bold AJ (2012) Brain natriuretic peptide production and secretion in inflammation. J Transp Secur 2012:962347–962347. https://doi.org/10.2147/jts.2012.962347

Cantinotti M, Giovannini S, Murzi B, Clerico A (2011) Diagnostic, prognostic and therapeutic relevance of B-type natriuretic hormone and related peptides in children with congenital heart diseases. Clin Chem Lab Med 49:567–580. https://doi.org/10.1515/cclm.2011.106

Eindhoff JA, Van Den Bosch AE, Boersma E, Roos-Hesselink JW (2013) The usefulness of brain natriuretic peptide in simple congenital heart disease—a systematic review. Cardiol Young 23:315–324. https://doi.org/10.1038/cy.2012.0035-1548540

Jobe AH, Bancelari E (2001) Bronchopulmonary dysplasia. Am J Respir Crit Care Med 163:1723–1729. https://doi.org/10.1164/acjcc.163.7.2011060

Krishnan U, Feinstein A, Adatia I, Austin ED, Mullen MP, Hopper RK, Hamna B, Romer L, Keller RL, Fineman J, Steinhorn R, Kinsella JP, Iy DD, Rosenzweig EB, Raj U, Humph T, Abman SH, Coulson J, Collaco M, Grendols A (2017) Evaluation and management of pulmonary hypertension in children with bronchopulmonary dysplasia. J Pediatr 188:24–34. https://doi.org/10.1016/j.jpeds.2017.05.029

A Second International Committee for the Classification of Retinopathy of Prematurity (2005) The international classification
33. Papile L, Burstein J, Burstein R, Koffler H (1973) Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1500 gm. J Pediatr 92:529–534. https://doi.org/10.1016/S0022-3476(78)80282-0

34. Lee JS, Polin RA (2003) Treatment and prevention of necrotizing enterocolitis. Semin Neonatol 8:449–459. https://doi.org/10.1016/S1084-2756(03)00123-4

35. De Vecchis R, Ariano C (2016) Measuring B-type natriuretic peptide from capillary blood or venous sample: is it the same? Cardiol Res 7:51–58. https://doi.org/10.14740/cr468e

36. Martin J, Smith J, Bastien M et al (2011) Comparison between arterial and venous sampling of circulating hormones, substrates and peptides in severe obesity. Clin Invest Med 34:82–87. https://doi.org/10.25011/cim.v34i1.15104

37. Roche Diagnostics GmbH, Mannheim, Germany (2020) Elecsys proBNP II [package insert]. Available at: www.mylabonline.com

38. Prontera C, Carlo G, Vittorini S et al (2009) Comparison between analytical performances of polyclonal and monoclonal electrochemiluminescence immunoassays for NT-proBNP. Clin Chim Acta 400:70–73. https://doi.org/10.1016/j.cca.2008.10.011

39. Sykes E, Karcher RE, Eisenstadt J, Tushman DA, Balasubramaniam M, Gusway J, Peterson VJ (2005) Analytical relationships among Biosite, Bayer, and Roche methods for BNP and NT-proBNP: a preliminary study. Am J Clin Pathol 123:584–590. https://doi.org/10.1309/F86FVEFDGX06DTUV

40. Collin-Chavagnac D, Dehoux M, Schellenberg F, Cauliez B (2015) Head-to-head comparison of 10 natriuretic peptide assays. Clin Chem Lab Med 53:1825–1837. https://doi.org/10.1515/cclm-2014-0592

41. Nir A, Lindinger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L, Koch A, Falkenberg J, Mir TS (2009) NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 30:3–8. https://doi.org/10.1007/s00246-008-9258-4

42. Tauber KA, Doyle R, Granina E, Munshi U (2016) B-type natriuretic peptide levels normalise in preterm infants without a patent ductus arteriosus by the fifth postnatal day. Acta Paediatr 105:352–355. https://doi.org/10.1111/apa.13480

43. Da Graca RL, Hassinger DC, Flynn PA et al (2006) Longitudinal changes of brain-type natriuretic peptide in preterm neonates. Pediatrics 117:2183–2189. https://doi.org/10.1542/peds.2005-1387

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.